肿瘤细胞治疗研究
英文原题：GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?
过去十年中，CAR-T 细胞已成为部分血液系统恶性肿瘤的突破性癌症疗法。
过去十年，CAR-T 细胞已成为治疗部分血液系统恶性肿瘤的突破性疗法。将该疗法的成功转化至实体瘤治疗仍具挑战。本期文章讨论了可能有助于提高 CAR T 细胞治疗实体瘤疗效的策略。参见 Fischer-Riepe 等人相关文章，第 3564 页。
Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication. See related article by Fischer-Riepe et al., p. 3564.
MEMBER ACCOUNT
登录成功会直接打开下一页。
